As demonstrated for TNF-mediated necroptosis,30 RIPK3-expressing A375 (Figures 4a and b) or, to a lesser extent, IGR melanoma cells (Supplementary Figure 2B and C, lower result panel), but not control transduced melanoma cells, were not fully protected from IAP antagonist/CD95L treatment by ZVAD-fmk and Nec-1 (Figure 4a). Here, RIPK3 is linked to melanoma.